Acacia Research Corporation — Q3 2014 Form 10-Q
Business and reporting period: Acacia’s operating subsidiaries acquire or control patent rights and generate revenue by licensing and enforcing those rights. This unaudited report covers the three and nine months ended September 30, 2014; comparisons are with the same 2013 periods.
Financial performance
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $37.2 million | $15.5 million | $99.8 million | $115.5 million |
| Operating loss | $12.6 million | $35.3 million | $46.9 million | $51.2 million |
| Net loss attributable to Acacia | $12.4 million | $15.7 million | $49.8 million | $23.1 million |
| Basic and diluted loss per share | $0.26 | $0.33 | $1.04 | $0.49 |
| Operating margin | (34.0%) | (227.7%) | (47.0%) | (44.3%) |
- Q3 revenue rose 140%, primarily as average revenue per agreement increased to $1.86 million from $647,000; agreements executed declined from 24 to 20. Nine-month revenue fell 14%, as 55 agreements were executed versus 96, partly offset by higher average revenue per agreement.
- Q3 operating loss narrowed as revenue increased and marketing, general and administrative expense declined 36%. Nine-month net loss more than doubled, in part reflecting the prior-year tax benefit; nine-month pretax loss improved 4%.
- Q3 inventor royalties and contingent legal fees combined rose 152% to $12.3 million. Nine-month combined expense declined 32% to $32.6 million. Patent amortization rose 18% year to date to $43.5 million, including a $2.6 million partial portfolio write-down.
- Cash from operations was $13.9 million for the first nine months, versus cash used of $4.8 million in 2013. Investing activities provided $33.1 million, including net proceeds from available-for-sale investments; financing used $19.4 million, primarily for dividends.
Financial position and liquidity
- At September 30, 2014, cash and cash equivalents were $154.3 million and short-term investments were $72.5 million, totaling $226.7 million. This compares with $256.7 million at December 31, 2013.
- Working capital was $210.0 million, down from $247.7 million. Current assets were $248.4 million and current liabilities $38.3 million. The filing reports no long-term debt or credit facilities.
- Accounts receivable increased to $12.7 million from $6.3 million; royalties and contingent legal fees payable increased to $17.8 million from $10.4 million. Management said most receivables were collected or due in Q4 2014 and most related payables were due in Q4 2014 or Q1 2015.
- Patent assets, net, were $269.4 million. Nine-month patent investment payments were $24.5 million. Dividends paid in the period totaled $18.8 million; the quarterly dividend was $0.125 per share.
Outlook, risks and unusual items
- Management believed cash, investments and anticipated operating cash flows would meet cash requirements through at least November 2015. No earnings or revenue guidance was provided.
- Management emphasized that licensing revenue can fluctuate significantly with agreement timing, litigation outcomes, portfolio mix and other factors, and that it does not manage for smooth sequential growth. It is shifting toward fewer, higher-quality patent portfolios and pursuing international and new partnering opportunities.
- Acacia accrued $1.548 million for two patent cases deemed “exceptional” by federal courts; defendants requested a total of $2.8 million, and the subsidiaries challenged the amounts, including by filing an appeal. Separately, a California insurance-fraud-prevention lawsuit was awaiting a judge’s ruling after trial and post-trial briefing; management believed it would not materially affect financial condition, results or liquidity but could not assure success.
- Revenue concentration was significant: three licensees represented 43%, 30% and 12% of Q3 revenue. Patent enforcement carries potential legal-cost awards or sanctions, while patent litigation and licensing expenses are expected to fluctuate. Management also cited risks from legislative or regulatory changes affecting patent enforcement.
- The 2014 tax provision included foreign withholding taxes and valuation allowances on certain tax assets; the effective tax rate was 7% for the nine-month period, versus a tax benefit and effective rate of (52%) in 2013. Unrealized losses on U.S. government securities were recorded in other comprehensive loss; the company reported no credit-loss impairment.
Important facts for investors to verify
- Whether revenue growth and cash collections persist, given the decline in year-to-date agreements and the concentration of revenue among a few licensees.
- Outcomes and potential costs of the exceptional-case appeals and the pending California lawsuit, including whether recorded accruals prove adequate.
- Patent portfolio performance and recoverability, including the $2.6 million write-down, amortization burden and continued patent investment requirements.
- Liquidity against operating costs, dividend payments and legal obligations, particularly if licensing receipts are delayed or weaker than expected.
- Future tax expense and the recoverability of tax assets subject to valuation allowances.